Speakers

Expand/Collapse

Ercem Atillasoy
Chief Regulatory & Safety Officer
AlloVir

Day One

Wednesday April 21

12:30 pm | Q&A/Discussion

11:40 am | Expedited Regulatory Pathways for Development & Licensure of Novel Anti-Infectives

Martin Everett
Chief Scientific Officer
AntaBio

Day One

Wednesday April 21

4:50 pm | Q&A/Discussion

4:00 pm | Pseudomonas Elastase (LasB) as a Therapeutic Target

Glenn Dale
Chief Development Officer
BioVersys

Day Two

Thursday April 22

12:30 pm | Q&A/Discussion

11:15 am | BV100 – a Novel Therapy for Antibiotic-Resistant Acinetobacter Infections

Kevin Outterson
Executive Director & Professor of Law
CARB-X & Boston University

Day One

Wednesday April 21

10:15 am | Q&A/Discussion

9:25 am | Surviving FDA Approval of your Antibiotic

Cara Cassino
Executive Vice President of R&D & Chief Medical Officer
ContraFect

Day Two

Thursday April 22

9:50 am | Q&A/Discussion

9:00 am | Direct Lytic Agents (DLA): New Medical Modalities for Life- Threatening, Drug-Resistant Infections

David Altarac
Chief Medical Officer
Entasis Therapeutics

Day Two

Thursday April 22

12:30 pm | Q&A/Discussion

12:05 pm | Targeted Therapy for Rare Pathogens: Challenges & Opportunities

Marc Navre
Chief Executive Officer & Chief Scientific Officer
Facile Therapeutics

Day One

Wednesday April 21

4:50 pm | Q&A/Discussion

4:25 pm | A De-Risked Small Molecule Anti-Toxin for the Treatment of C.difficile Infections

Dave Ousterout
Chief Scientific Officer
Locus Biosciences

Day One

Wednesday April 21

2:40 pm | Q&A/Discussion

1:50 pm | Clinical Experience with crPhage in Urinary Tract Infections

Silas Holland
Head of External Affairs (Interim) & Director of Global Public Policy
The AMR Action Fund & Merck

Day One

Wednesday April 21

10:15 am | Q&A/Discussion

9:00 am | AMR Action Fund: Strengthening & Accelerating Antibiotic Development

Mike Gordeev
Chief Scientific Officer
MicuRx Pharmaceuticals

Day Two

Thursday April 22

2:50 pm | Q&A/Discussion

2:25 pm | Novel Investigational Polymyxin MRX-8 with an Improved Safety & Efficacy against Key Gram-Negative Infections

John George
Co-Founder & Chief Scientific Officer
Oppilotech

Ed Siegwart
Director of Microbiology
Oppilotech

Jonathan Steckbeck
Founder, President & Chief Executive Officer
Peptilogics

Day One

Wednesday April 21

12:30 pm | Q&A/Discussion

12:05 pm | Differentiated Approach to Harnessing Novel Biologics & Overcome AMR

Jeanette Mucha
Chief Executive Officer & Co- Founder
SciBac

Day One

Wednesday April 21

2:40 pm | Q&A/Discussion

2:15 pm | Fighting Fire with Fire: Live Biotherapeutics for Pulmonary Infections

Angela Talley
Vice President of Clinical Development
Spero Therapeutics

Day Two

Thursday April 22

12:30 pm | Q&A/Discussion

11:40 am | Ensuring Anti-Infective Economic Sustainability by Targeting the Unmet Medical Need

David Powell
Chief Scientific Officer
Summit Therapeutics

Day Two

Thursday April 22

9:50 am | Q&A/Discussion

9:25 am | Building a Pipeline of New Mechanism Antibiotics that Drives Commercial Sustainability through Clinical Superiority

Nrusingh Mohapatra
Chief Scientific Officer
Techulon

Day Two

Thursday April 22

2:50 pm | Q&A/Discussion

2:00 pm | Obstacles for Discovery & Development of Narrow Spectrum Antimicrobials

Joseph DiMasi
Director of Economic Analysis
Tufts CSDD

Day One

Wednesday April 21

10:15 am | Q&A/Discussion

9:50 am | Trends in the Development & Approval of New Anti-infectives: Cycle Times, Success Rates & Expedited Regulatory Pathways

Silvia Caballero
Associate Director of Infectious Diseases
Vedanta Biosciences

Bernat Olle
Chief Executive Officer
Vedanta Biosciences

James Crowe
Director
Vanderbilt Vaccine Center

Mohammad Seyedsayamdost
Associate Professor of Chemistry & Molecular Biology
Princeton University

Peter Beyer
Senior Advisor and Team Lead
World Health Organization - WHO

Day One

Wednesday April 21

8:30 am | Keynote Presentation: A Review of the Antibacterial Development Pipeline